On April 10, 2026, Evofem Biosciences, Inc. amended its agreement with Adjuvant Global Health Technology Fund, changing the payment terms of certain notes that are due six months after the amendment date or upon a Change of Control. The notes cannot be prepaid prior to that six-month period without consent from Adjuvant.